Dizal’s Zegfrovy: A Breakthrough in NSCLC Treatment with FDA Approval
Dizal Jiangsu Pharmaceutical Co Ltd has achieved a significant milestone with the FDA’s accelerated approval of its innovative cancer treatment, Zegfrovy, for non-small cell lung cancer patients with EGFR Exon20ins mutations.
3 minutes to read